Two words made the crossing from Korean clinics to American shelves faster than almost anything in recent memory. Exosome and PDRN now appear on retail packaging, in treatment menus, on clinic websites and in supplier decks, often in the same week and often describing three completely different things. The vocabulary traveled. The regulatory status did not travel with it, and that gap is where operators are currently getting hurt.
This is not an ingredient story. The ingredient story was written a year ago. This is a story about what a word is allowed to mean in each market, and what happens at the treatment room door when the answer differs.
What actually crossed the ocean
The clearest marker of how mainstream this has become arrived in February. On 11 February 2026, Mediheal placed its PDRN Collection into more than 1,400 Ulta Beauty stores nationwide. Not a specialty channel, not a clinic account, not a DTC launch. Fourteen hundred doors of mass prestige retail.
The detail worth pausing on is in the formulation. The Ulta range is built on vegan PDRN derived from rose, not the salmon-derived polynucleotide that made the ingredient famous in Korean clinics. Same three letters on the front of the box. Different biological source, different supply chain, different regulatory conversation.
The category behind it is real and growing at an unremarkable, sustainable rate rather than a hype rate. The PDRN market was valued at USD 321.2 million in 2025 and is projected to reach USD 811.4 million by 2035, a 9.7 percent CAGR. Korea sits at the center of supply: South Korea accounts for more than half of global PDRN manufacturing, with Korea, Italy and China together supplying roughly 71 percent of global volume in 2025. On the professional side, North American dermatologists have reported a 37 percent increase in the use of topical PDRN since 2023. In Korea itself, PharmaResearch states that its Rejuran line, built on polynucleotide technology, has been used by more than 500,000 people annually since its 2014 launch.
So the demand is genuine, the supply is concentrated in Korea, and the retail version has already gone national. Everything about that is a normal import story. The abnormal part is the compliance layer underneath.
Korea drew its line first
Korea’s regulator reached the confusion problem before the U.S. market did, and responded by restricting the language rather than the ingredient.
On 21 January 2025, the MFDS expanded the list of prohibited expressions in its cosmetic labeling and advertising guidelines. Four categories matter for anyone sourcing Korean product:
- Human-derived ingredient terms, including “exosome,” are prohibited in cosmetic advertising unless the ingredient is clearly plant or animal derived.
- Claims implying medical settings or exclusivity, such as hospital-only or dermatology-only positioning, are prohibited.
- Device and procedure terminology, such as microneedle language applied to a cosmetic, is restricted.
- Quantitative anti-aging claims, of the reduces-your-skin-age-by-X-years variety, are prohibited.
Enforcement followed quickly. By 26 May 2025, MFDS inspections had reported 237 online advertising violations, with roughly 48 percent judged capable of being mistaken for drug or medical claims, much of it tied to exosome and stem-cell wording or hospital-exclusive phrasing.
On the ingredient side rather than the claim side, Korea’s position is narrower than the marketing suggests. Human cells, tissues and their culture media are prohibited in cosmetics except where they meet the specific safety standards set out in the cosmetics safety regulation. Non-human exosomes carry no equivalent dedicated requirement and are assessed case by case.
The practical translation for a U.S. buyer: a Korean brand that cannot say “exosome” on its own domestic packaging may still be presented to you with an exosome-led sell sheet built for export. The restraint you see in the Korean listing is not modesty. It is a rule.
The U.S. line sits somewhere else entirely
The FDA has not restricted a word. It has taken a position on a product class, and it is considerably harder.
No exosome product has been approved for aesthetic use in the United States. FDA’s public safety notification on exosome products holds that administering unapproved exosome products to patients violates federal law, because such products are regulated as biologics rather than as cosmetics.
Enforcement has been steady rather than theatrical. Between late 2024 and early 2026 the agency issued letters across the chain, to manufacturers, distributors and administering providers. In early 2025 Chara Biologics was warned that its CharaExo product was an unapproved new drug and an unlicensed biological product. In September 2025, New Life Medical Services received a warning letter over its exosome product Rexo, again on unapproved new drug and unlawful biologic marketing grounds. Reported adverse events tied to unapproved exosome products have included serious infections.
Topical application without injection sits in a softer position than injection does, but softer is not the same as settled, and pairing a topical with a procedure that breaks the skin barrier moves the question back toward the drug side of the line.
Three products, one word
Most of the operator confusion resolves once you stop treating exosome and PDRN as ingredients and start treating them as three separate product classes that happen to share vocabulary.
- The retail cosmetic. A plant-derived or fish-derived topical sold as a cosmetic, making cosmetic claims. This is what went into 1,400 Ulta doors. It is importable, listable under MoCRA, and sellable on a retail shelf.
- The professional topical. The same chemistry, sold into clinics with a professional protocol attached. Legally still a cosmetic if the claims stay cosmetic. The risk here is entirely in what the treatment menu and the consultation say, not in the bottle.
- The injectable. A biologic or a drug. Not a sourcing decision, not a cosmetic decision, and not something a distributor can make compliant by relabeling it.
A supplier who blurs those three in a single line sheet is not offering you a portfolio. They are offering you their regulatory exposure.
What to establish before the first order
- Ask for the biological source in writing. Rose, salmon, other. Vegan PDRN and salmon PDRN are not interchangeable claims and should never appear under one spec sheet.
- Get the Korean domestic listing alongside the export deck. If the domestic version avoids the word and the export version leads with it, you have found the gap.
- Separate the bottle from the protocol. Approve the product and the treatment menu language as two distinct reviews, by two distinct standards.
- Refuse injectable adjacency. No exosome injectables, no supplier who bundles them with topicals, no consultation script that implies one.
- Audit what your own front desk says. Most claim risk in a clinic is verbal and undocumented, spoken in the consultation rather than printed on the shelf talker.
The operator’s view
Regenerative actives are not a fad and the demand is not manufactured. Korea genuinely leads the science and the supply, U.S. clinicians are genuinely using more of it, and the retail category has already proved it can hold national distribution.
What has not happened is convergence on what the words mean. Korea restricted the vocabulary and left the ingredient largely available. The U.S. left the vocabulary alone and restricted the product class. An operator standing between those two systems can be entirely correct in one market while being in violation in the other, and the sell sheet in front of them will not mention it.
Luxmetics sources these categories with the source, the claim set and the regulatory class documented before a sample ships, because the alternative is discovering the classification after the product is on a shelf or in a treatment room. The interesting work in K-beauty right now is at the professional tier. The condition of doing it profitably is knowing exactly which of the three products you just bought.